Abstract
Transcutaneous immunization (TCI) with dissolving microneedle arrays (DMAs) is a promising vaccine administration method. In this work, we developed a TCI device consisting of dissolving polyvinylpyrrolidone (PVP) microneedles array, where in the tips are loaded with antigen and adjuvant encapsulated in liposomes. The microneedles could effectively be inserted into the skin and completely dissolve within 3 min. As a test-case, we selected ovalbumin (OVA) as a model antigen, CpG OND as adjuvant and cationic liposome (Lip) as a microparticulate vehicle for co-deliver antigens and adjuvant. Mice were immunized transcutaneously with DMAs containing OVA, OVA-CpG OND, OVA encapsulated in Lip, OVA-CpG OND encapsulated in Lip and conventional intramuscular injection (IM) with OVA solution, respectively. The results show that the anti-OVA IgG antibody level in the group immunized with the DMA containing OVA-CpG OND encapsulated in Lip was significantly higher than that of the other groups. Furthermore, it significantly increased the level of IgG2a (P<0.05) and achieved the shift of immune type from predominate Th2 type to a balance Th1/Th2 type. In conclusion, the DMA TCI device can effectively deliver the Lip encapsulating CpG OND-OVA into skin, enhancing the immune response and change the immune type.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
